Tradestie Institutional Equity Comparison Engine

BGLC vs OIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BGLC Overall Edge

BGLC Captures Institutional Edge (1โ€“1 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BioNexus Gene Lab Corp Common stock (BGLC) driven by superior Growth & Margin while OIO counters with relative strength in Momentum & Technical. Fundamentally, BGLC trades at N/M Forward P/E with -88.2% operating margin (-96.6% YoY revenue) versus OIO at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, BGLC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against OIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BGLC N/M vs OIO N/M Fwd P/E
Growth & Margin Winner BGLC
Op Margin -88.2% vs N/A ยท YoY -96.6% vs N/A
Momentum & Technical Winner OIO
1Y -86.2% vs -56.5% ยท 52W Pos 1% vs 5%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
BGLC NASDAQ
BioNexus Gene Lab Corp Common stock
Services-Medical Laboratories
$0.71
-13.43% 1D
Market Cap $2.4M
1M Return -42.19%
1Y Return -86.22%
Forward P/E N/M
Unified AI Score
47.9 / 100 HOLD
Tech 53.0 Fund 56.0 Flow 50.0 Mom 60.0
OIO US Equity
OIO
Institutional Equity
$1.68
-1.38% 1D
Market Cap N/A
1M Return -6.86%
1Y Return -56.45%
Forward P/E N/M
Unified AI Score
36.4 / 100 SELL
Tech 22.0 Fund 37.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BGLC -86.22% OIO -56.45% Spread: +10.99 pp (OIO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BGLC TTM Op. Margin: -88.2% OIO TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGLC vs OIO. Trailing 12-month operating profitability (BGLC -88.2% vs OIO N/A) and valuation multiples (BGLC N/M vs OIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BGLC (6) vs OIO (2)
Institutional Metric BGLC OIO Criterion Row Winner
Market Capitalization Scale $2.4M N/A Larger Scale BGLC
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -96.6% N/A Higher Growth BGLC
Operating Margin (TTM) Profitability -88.2% N/A Higher Margin BGLC
Net Profit Margin Profitability -82.4% N/A Higher Margin BGLC
Return on Equity (ROE) Capital Efficiency -33.7% N/A Higher ROE BGLC
52-Week Range Position Momentum 1% ($1โ€“$5) 5% ($1โ€“$8) Stronger Trend OIO
Beta / 30D Volatility Risk Regime 1.33ฮฒ ยท 84% Vol -0.14ฮฒ ยท 53% Vol Lower Realized Risk OIO
Unified Institutional Score Composite Signal 47.9 / 100 (HOLD) 36.4 / 100 (SELL) Higher Composite BGLC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BGLC vs OIO Buy Guide
BGLC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BGLC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
OIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live OIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BGLC nor OIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.